An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer

Clinical Lung Cancer

Volumn 16, Issue 2, 2015, Pages 92-99

  Waller, Cornelius F ^a   Vynnychenko, Ihor ^b   Bondarenko, Igor ^c   Shparyk, Yaroslav ^d   Hodge, Jeffrey P ^e   Freeman, Anne ^e   Huber, Brian ^e   Lieberman, Ronald ^e   Shelton, Mark J ^e   Dave, Harish ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SUMY STATE UNIVERSITY   (Ukraine)

^c DONETSK MEDICAL UNIVERSITY   (Ukraine)

^d Lviv Regional State Clinical Treatment and Diagnostic Endocrinology Center   (Ukraine)

^e IQVIA   (United States)

Author keywords

Eribulin mesylate; Overall survival; Phase II clinical trial; Progression free survival; Time to progression

Indexed keywords

DEXAMETHASONE; ERIBULIN; PEMETREXED; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FURAN DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; KETONE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; HYPERTRANSAMINASEMIA; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT FAILURE; VERY ELDERLY; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FURANS; GLUTAMATES; GUANINE; HUMANS; KETONES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84924018386     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.10.001     Document Type: Article

References (23)

1. J.R. Molina, P. Yang, and S.D. Cassivi Non-small-cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 83 2008 584 594
2. S. Navada, P. Lai, and A.G. Schwartz Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database (abstract 7082) J Clin Oncol 24 18 suppl 2006 384S
3. T. Sher, G.K. Dy, and A.A. Adjei Small cell lung cancer Mayo Clin Proc 83 2008 355 367
4. Chemotherapy for non-small-cell lung cancer. Non-Small-Cell Lung Cancer Collaborative Group Cochrane Database Syst Rev 2000 CD002139
5. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
6. Taxotere (docetaxel) [prescribing information] 2010 Sanofi-Aventis U.S. LLC Bridgewater, NJ
7. F.A. Shepherd, J. Dancey, and R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
8. F.V. Fossella, R. DeVore, and R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group J Clin Oncol 18 2000 2354 2362
9. Alimta (pemetrexed disodium) [prescribing information] 2013 Eli Lilly and Company Indianapolis, IN
10. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
11. Tarceva (erlotinib) [prescribing information] 2013 OSI Pharmaceuticals, Inc, and Genentech, Inc South San Francisco, CA
12. F.A. Shepherd, P.J. Rodrigues, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
13. Iressa (gefitinib) [prescribing information] 2005 AstraZeneca Pharmaceuticals LP Wilmington, DE
14. E.S. Kim, V. Hirsh, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
15. N. Thatcher, A. Chang, and P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
16. Halaven (eribulin mesylate) [prescribing information] 2013 Eisai R&D Management Co Ltd Woodcliff Lake, NJ
17. A.I. Spira, N.O. Iannotti, and M.A. Savin A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer Clin Lung Cancer 13 2012 31 38
18. B.J. Gitlitz, D.D. Tsao-Wei, and S. Groshen A phase II study of Halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small-cell lung cancer previously treated with a taxane J Thorac Oncol 7 2012 574 578
19. J. Cortes, J. O'Shaughnessy, and D. Loesch Eribulin monotherapy versus treatment physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label study Lancet 377 2011 914 923
20. J. Cortes, L. Vahdat, and J.L. Blum Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine J Clin Oncol 28 2010 3922 3928
21. K. Aogi, H. Iwata, and N. Masuda A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer Ann Oncol 23 2012 1441 1448
22. P. Poletti, V. Ghilardi, and L. Livraghi Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital Future Oncol 10 2014 233 239
23. U. Swami, I. Chaudhary, and M.H. Ghalib Eribulin- a review of preclinical and clinical studies Crit Rev Oncol Hematol 81 2012 163 184